When living with AFP-High* liver cancer (HCC)...
The little things feel even bigger. So I fight even harder.
CYRAMZA (ramucirumab) is used by itself to treat a type of liver cancer called hepatocellular carcinoma (HCC). CYRAMZA is for people who have levels of alphafetoprotein of at least 400 nanograms per milliliter (ng/mL) (AFP-High) in their blood and have been treated with another type of chemotherapy medicine called sorafenib.
SELECT SAFETY INFORMATION
CYRAMZA may cause serious side effects, including:
Severe bleeding, including bleeding in the stomach or bowel, has happened with CYRAMZA. This can be life threatening. Tell your doctor right away if you have bleeding or symptoms of bleeding, including lightheadedness. If severe bleeding happens, you will have to stop receiving CYRAMZA.
Understanding your condition
Cancer that starts in the liver is known as primary liver cancer. Hepatocellular cancer (HCC) is the most common form of liver cancer in adults. This type of cancer has 2 main growth patterns: a single tumor that grows larger and only spreads late in the disease, or multiple small tumors seen throughout the liver. The latter pattern is typically found in people who have a history of cirrhosis, or chronic liver damage. It is also the most common pattern seen in the United States.